Figure 6. Effector mechanisms involved in anti−tumor effects of TriVax.

(A), B6 mice (8 per group) received with 1 × 10 ⁵ B16F10 cells i.v. Various subsets of immune effector cells (CD8 T cells, CD4 T cells or NK cells) were depleted using mAb on days −3 and −1 before receiving the TriVax injection. An addition mAb injection was administered 2 days after vaccinatioin. TriVax immunizations were administered on days 3 and 14 after tumor injections. Kaplan–Mayer survival curves for all groups of mice are shown. P values were determined by log-rank tests. (B), Therapeutic effects of Trp2_180–188-TriVax in WT B6 mice (WT), IFNγ^−/−, IFNαβR^−/−, and Prf^−/− mice were evaluated a described above. Results were evaluated for statistical significance using log-rank test. (C), In a parallel experiment freshly isolated spleen CD8 T cells from WT, IFNγ^−/−, IFNαβR^−/−, mice were tested for cytolytic activity in a 5-h ⁵¹Cr-release assay as described in Figure 2C.